No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults by Rajinder Bhardwaj, Michael S. Hanna, Beth A. Morris, Kyle T. Matschke, Richard Bertz, Robert S. Croop, Jing Liu

Connect to this object online.

Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects by Rajinder Bhardwaj, Mary Donohue, Jennifer Madonia, Matt S. Anderson, Kyle Matschke, Richard Bertz, Robert Croop, Jing Liu

Connect to this object online.

Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment by Rajinder Bhardwaj, Mary K. Donohue, Jennifer Madonia, Beth Morris, Thomas C. Marbury, Kyle T. Matschke, Robert Croop, Richard Bertz, Jing Liu

Connect to this object online.

Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval by Jim H. Hughes, Richard Bertz, Rajinder Bhardwaj, Mary K. Donohue, Jennifer Madonia, Matt S. Anderson, Beth A. Morris, Robert S. Croop, Jing Liu

Connect to this object online.